MacroGenics, Inc.
Antibodies reactive with B7-H3 and users thereof
Last updated:
Abstract:
The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
Status:
Grant
Type:
Utility
Filling date:
4 Jan 2018
Issue date:
4 Aug 2020